Loading…
← CockpitCompetitor Analysis › M12.DE M1 Kliniken AGOpen in the cockpit ↗

M1 Kliniken AGM12.DECompetitor analysis, valuation and peers

Germany · EUR·Health Care›Medical/Nursing Services
Momentum strong 67
Mkt cap
$368M
US dollars, full cap
Free float
34%
of shares outstanding
$/day
$97,400
20-day average traded
Fwd P/E
16.4×
forward earnings
ROIC−WACC
+11.5 pp
WACC 6.5%
Hurdle
-23 pp
Req g minus delivered
Close · EUR€19.08
1D-2.4%
1W-2.0%
1M+0.5%
3M+4.8%
6M+0.5%
YTD+0.4%
1Y+20.0%
ATR %3.5%
52w lowhigh12.1% off high

What M1 Kliniken does

No business profile yet.

M1 Kliniken at a glance

Size M1 Kliniken (M12.DE) is a Germany Health Care company (Medical/Nursing Services) with a market value of $368M, the 186th largest of 198 Germany companies the cockpit tracks. Shares closed at €19.08 on 18 Nov 2026.

Performance Over six months the shares gained 0.5%, against -4.0% for the median peer and -0.9% for the Germany market (cap-weighted) — 8th highest of 20 in its peer set.

Growth Revenue fell 27.5% over the last twelve months (peer median +6.0%); the operating margin is 12.5% (peer median 8.0%).

Valuation It trades at 16.4× forward earnings against a peer median of 17.6× (6th cheapest of 13).

Price implies For today's price to make sense, revenue must grow about -5% a year for seven years (Req g). Recent delivered growth is +18%, so the hurdle is -23 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 11.5 points above its cost of capital (6.5% WACC).

Relative performance

9010011021 May 202621 Aug 202618 Nov 2026M12.DE 101Peer median 96
Six months, rebased to 100: M1 Kliniken against the median of its 20 peers (local-currency closes).

M1 Kliniken financials

Reported figures in EUR; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue€257M€364M€339M€316M€285M
Revenue growth—+7%+7%+11%—
Gross profit€47.7M€47.4M€37.9M€26.7M€21.7M
EBITDA€36.6M€40.7M€31.1M€19.6M€14.6M
Net income€20.2M€22.1M€16.0M€10.3M€4.32M
Free cash flow€23.1M€33.7M€29.8M€8.46M€19.9M
Capital expenditure€213,093€110,224€995,383€1.01M€1.77M
Total debtn/a€10.3M€21.1M€17.0M€19.7M

Quarterly statements and history in the cockpit →

M1 Kliniken competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%-20%0%+20%AYUPA9860JSLL300642IDXNIOXACLAUNASRTA127120DRAGARWQ301060DNAWELLFLGTNEPHROPLUSGMRSM12.DE6-month return →1-month return →
Up and to the right = strong over both horizons. M1 Kliniken is the large dot.

Fundamentals: revenue growth against valuation

0%+50%+100%0×25×50×75×9860JSLLIDXNIOXACLAUNASRTAWELLNEPHROPLUSGMRS1951M12.DERevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. M1 Kliniken is the large dot.

Capital: growth delivered against growth the price implies

0%+50%+100%0%50%100%AYUPA9860JSLL300642IDXSTLNACLAUNA3218DRAGARWQ301060WELLNEPHROPLUSGMRS1951M12.DEGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. M1 Kliniken is the large dot.

M1 Kliniken competitors and peer comparison

How M1 Kliniken compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

M1 Kliniken against its 20 peers (data as of 18 Nov 2026)
MeasureM12.DEPeer medianRank in peer set
1-month return+0.5%-9.6%9th highest of 21
6-month return+0.5%-4.0%8th highest of 20
Distance from 52-week high-12.1%-30.8%3rd highest of 21
Revenue growth (TTM)-27.5%+6.0%2nd lowest of 21
Operating margin12.5%8.0%7th highest of 21
Forward P/E16.4×17.6×6th cheapest of 13
Growth the price implies (Req g, 7 yrs)-5.3%6.6%5th least demanding of 17
Growth delivered (Del g)+17.9%+15.4%7th highest of 17
Hurdle (Req g minus delivered)-23.2 pp-10.9 pp6th least demanding of 17
ROIC minus cost of capital+11.5 pp-2.5 pp4th highest of 20
EV / EBITDA8.4×9.8×6th cheapest of 13
Net debt / EBITDA-1.5×1.6×2nd least indebted of 14

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
M1 Kliniken M12.DEGermany$368M+1%-28%13%16.4×-5.3%+17.9%
Australian Unity Ltd Pref AYUPA.AXAustralia$352M+17%0%-2%n/a-14.9%+9.6%
ADICON 9860.HKHong Kong$393M+5%+1%4%24.6×12.3%-1.5%
Jeena Sikho Lifecare JSLL.NSIndia$394M-55%+135%32%17.4×7.3%+42.6%
Tellgen 300642.SZChina$328M-11%+5%8%n/a18.8%-5.8%
Integral Diagnostics IDX.AXAustralia$413M-22%+26%9%14.7×7.8%+17.7%
Oncology Institute STLNUnited States$326Mn/a+35%-3%n/a5.4%+21.8%
NIOX NIOX.LUnited Kingdom$325M+3%+3%22%19.8×3.4%+15.3%
Australian Clinical Labs ACL.AXAustralia$418M+68%-1%8%17.8×4.3%+2.6%
Auna AUNAUnited States$309M-5%+17%13%4.1×-10.7%+24.4%
Universal Vision Biotechnology 3218.TWOTaiwan$309M-4%+5%31%9.2×-13.8%+15.4%
Strata Critical Medical SRTAUnited States$443M-10%+23%-4%86.3×n/an/a
JS Link 127120.KSSouth Korea$458M-62%+39%-83%n/an/an/a
Dr. Agarwal'S Eye Hospital DRAGARWQ.NSIndia$292M+14%+20%21%n/a19.6%+27.5%
Shanghai Labway Clinical Laboratory 301060.SZChina$518M-17%-19%6%n/a5.9%+3.2%
Ginkgo Bioworks DNAUnited States$547M+9%-44%-242%n/an/an/a
WELL Health Technologies WELL.TOCanada$661M-9%+29%6%10.1×10.1%+94.5%
Fulgent Genetics FLGTUnited States$702M+53%+5%-38%n/an/an/a
Nephrocare Health Services NEPHROPLUS.NSIndia$702M+1%+33%13%48.8×36.6%+31.6%
GMR Solutions GMRSUnited States$714M-8%-4%14%5.9×-19.6%-4.0%
Jinxin Fertility 1951.HKHong Kong$758M-4%+7%11%23.1×17.8%+12.4%

Questions

Which companies are M1 Kliniken's closest peers?
The cockpit's peer set: Australian Unity Ltd Pref (AYUPA.AX), ADICON (9860.HK), Jeena Sikho Lifecare (JSLL.NS), Tellgen (300642.SZ), Integral Diagnostics (IDX.AX), Oncology Institute (STLN), NIOX (NIOX.L), Australian Clinical Labs (ACL.AX).
Is M1 Kliniken expensive compared with its peers?
On forward p/e it trades at 16.4× against a peer median of 17.6×, 6th cheapest of 13 in its peer set. For today's price to make sense, revenue must grow about -5% a year for seven years (Req g). Recent delivered growth is +18%, so the hurdle is -23 pp: the price already allows for a slowdown.
How has M1 Kliniken stock performed?
Over six months to 18 Nov 2026 the shares returned +0.5% against -4.0% for the median peer; over one year +20.0%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.